Collaborations and
Co-Development

Strategic collaborations are at the core of our business, whether we out-license our PharmFilm® technology to reinvent medicines or in-license adjacent assets for development and commercialization. Aquestive partners to solve tough clinical and business challenges. We offer industry-leading scientific and regulatory expertise, integrated capabilities to test and deliver treatments, and best-in-class efficiency to get new solutions to patients.

Over 12 years of collaboration and pipeline success,
10+ proprietary and pipeline collaborations

10+

proprietary and pipeline collaborations

A foundation in CNS

Commercialization expertise across therapeutic areas

Two women working alongside a PharmFilm® manufacturing line

In-licensing

Aquestive is interested in assets that are complementary to our existing pipeline products in CNS, although we will consider products that meet our criteria in adjacent therapy areas. Typically, we look to in-license products for which most of the clinical trials have been conducted and that are either in the process of registration or are already registered and ready to commercialize. Our assessment processes for in-licensing opportunities are led by our business development team, supported by expertise from other functional areas of the business.

Strips of PharmFilm® on a conveyor belt in a pharmaceutical manufacturing facility

Out-licensing

Aquestive’s collaborators commercialize hundreds of millions of doses of PharmFilm® every year. We collaborate to deliver novel molecules in clinical development and to repurpose approved medications for the benefit of patients and caregivers. Aquestive maintains a robust and fully integrated infrastructure for managing projects from inception to commercial supply.

A record of reliability

A PharmFilm® medication arranged vertically

Optimizing usability
to meet unmet needs

SUBOXONE® logo

Aquestive and Indivior jointly developed SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII) in less than 4 years. The market leader for 8 years, SUBOXONE® has never experienced an out-of-stock occurrence.

ZUPLENZ® logo

Aquestive also licensed with Midatech to launch ZUPLENZ® (ondansetron) oral soluble film, an antiemetic lingual film indicated for the prevention of nausea and vomiting due to chemotherapy, radiation therapy, or surgery. Aquestive has been manufacturing ZUPLENZ® since 2010.

Development process

We work with collaborators to help determine the best techniques and processes for reformulating proven molecules on film, and we share our expertise across the continuum of development activities.

Versatile, adaptable, and scalable services with expert support every step of the way

Formulation Development

Feasibility and proof-of-concept studies

Clinical and commercial manufacturing

Regulatory filings and patent protection

Learn more about products produced in collaboration with Aquestive

SUBOXONE® is a registered trademark of Indivior UK Ltd.

ZUPLENZ® is a registered trademark of Midatech Pharma US Inc.

Please complete this form:

  • To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. If for any reason you no longer wish to receive information on Aquestive-sponsored clinical trials, you can contact us at any time by emailing info@aquestive.com or by calling 1-833-AQUESTV

Please complete the form below and click SEND to receive a copy of “Overcoming Solubility and Permeability Challenges,” a case study detailing the achievements made by Aquestive’s formulation team to create the diazepam buccal film.

  • To subscribe to receive marketing updates about diazepam buccal film and other products and services from Aquestive, please complete the form below. Please also review our privacy policy, which describes how we use and process your data. If for any reason you no longer wish to receive direct marketing materials, you can contact us at any time by emailing info@aquestive.com or by calling 1-833-AQUESTV.

Please complete the form to receive a demonstration kit for our PharmFilm® technology.

  • To subscribe to receive marketing updates about our PharmFilm® technology and other products and services from Aquestive, please complete the form below. Please also review our privacy policy, which describes how we use and process your data. If for any reason you no longer wish to receive direct marketing materials, you can contact us at any time by emailing info@aquestive.com or by calling 1-833-AQUESTV.

Please complete this form:

  • To subscribe to receive marketing updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. If for any reason you no longer wish to receive information on Aquestive-sponsored clinical trials, you can contact us at any time by emailing info@aquestive.com or by calling 1-833-AQUESTV.

To learn how PharmFilm can transform your product or to begin a discussion about in-licensing, please complete the following form:

  • To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. If for any reason you no longer wish to receive information on Aquestive-sponsored clinical trials, you can contact us at any time by emailing info@aquestive.com or by calling 1-833-AQUESTV